Sitemap

Pages

• About Us
  • Executive Leadership Team
  • Mission, vision & values
  • Our approach
  • History
• ACE
• Careers
  • Why join Ardena?
• Contact Us
• COVID-19 Solutions
• Drug Product
  Development & Manufacturing
  • Services
    • Drug Product Formulation Development
      • Lipid based formulations
      • Nanosuspensions
      • Solid dispersions
    • Drug Product Analytical Development & QC
      • Chromatographic methods
      • Dissolution methods
    • Drug Product Stability Studies
    • Drug Product Manufacturing
  • Highlights
  • Capabilities
• Drug Substance
  Development & Manufacturing
  • Services
    • Drug Substance Characterization
      • Molecular properties
      • Molecular structure confirmation
      • Powder properties
      • Solid state properties
    • Drug Substance Process Development
      • Route scouting
      • Crystallization process development
      • Process scale up
    • Drug Substance Analytical Development & QC
    • Drug Substance Stability Studies
    • Drug Substance Manufacturing
    • Solid State Research
      • Crystal structure by X-Ray
      • Solid form screening
      • Solid form selection
      • IP support
  • Highlights
  • Capabilities
• General Terms and Conditions
• Home
• How to comply with FDA and EMA regulations
• Legal entities Ardena
• Nanomedicine
• News & Insights
• Nitrosamines
• Privacy Policy
• Registration form
• Sitemap
• Thank you for your contact request
• Upcoming events
• Webinar Archives
• Clinical Logistics
  • Services
    • Packaging, Labelling & Clinical trial supply
    • Biosample collection kits, Logistics & Biorepository
  • Highlights
  • Capabilities
• Bioanalysis
  • Services
    • Discovery Support
    • Preclinical Bioanalysis
    • Clinical Bioanalysis
    • Biomarkers
  • Highlights
  • Capabilities
• Dossier Development
  • Services
    • Scientific Report Writing
    • Quality Document Writing
    • Regulatory Dossier Writing
    • Submission and Liaison
  • Highlights
  • Capabilities

Posts by category

• Category: Events
• Category: Insights
  • Launch new Ardena career page
  • Patrick Walleser, new Ardena Account Management Director DACH region
  • EMA and FDA have activated plans to fast track the development and approval of therapeutics against COVID-19.
  • EMA extends nitrosamine risk assessments to investigational drugs
  • EMA request for Nitrosamine Risk Assessment
• Category: News
  • Parvus Therapeutics and Ardena Enter Agreement for Tech Transfer, Scale-Up and GMP Manufacturing of Navacim Nanoparticles
  • Steve Kendall, Ph.D. MBA, new Ardena Director of Business Development US.
  • Ardena acquires Idifarma from Suanfarma, adding spray drying technology and high potency capabilities
  • Ardena’s expertise on drug substance development helps new treatment for Parkinson’s disease to the next phase
  • Ardena’s success leads to major €35 million investment for expansion in Belgium, Sweden and The Netherlands
  • Citryll enters into bioanalytics partnership with Ardena for the clinical development of CIT-013, antagonist of NET biology and associated pathologies
  • Commercial Agency Agreement between Ardena and South Korean company Keyfronbio Co., Ltd.
  • Investment in Flow Cytometry unlocks the secrets of single cells
  • New cancer immunotherapy treatment enters clinical phase
  • Commercial Agency Agreement Taiwan (ROC)
  • CVC Credit Partners refinances Ardena’s credit facilities
  • Ardena Assen is doubling its capacity – Update 25.03.2020
  • GHO Capital acquires Ardena
  • Ardena Assen is doubling its capacity
  • BVA award nominee
  • Ardena launches Life Science Ingredients Arm
  • Ardena launches bimonthly newsletter
  • Ardena cements growth and expansion with new headquarters
  • Ardena expands nanomedicine capabilities
  • Ardena acquires Syntagon and strengthens API offering
  • Ardena acquires ChemConnection adding API expertise
  • Ardena is expanding its Belgian site
  • ABL acquisition extends early-phase offering
  • Ardena launches following Pharmavize and Crystallics merger
  • Category: Press Release
• Category: Whitepaper
  • Formulation and Process Considerations for Optimising Spray-Dried Solid Dispersions
  • Much more than just smoke – from marijuana to medicinal cannabis derived therapeutics
  • Leverage the power of CMC in early drug development
  • Prevent undesired immunogenicity from becoming the barrier for innovative biotherapeutics
  • Discriminatory dissolution test method in late development
  • Scientific Advice and Dialogue with EMA during Drug Development
  • Oligonucleotide therapeutics: How to measure plasma concentration, tissue distribution and immunogenicity?
  • Powder blending in early-phase drug product development: Balancing art and science
  • How to obtain enantiopure drug substance through crystallization?
  • How to enhance the safety of your drug substance synthesis process by smart chemical design?
  • Ardena launches integrated drug discovery support services
  • How to save significantly on early-phase clinical supply logistics?
  • Which solubility-enhancing technology should I use to support my early drug development project?
  • What is an acceptable impurity level for a drug substance used in GLP toxicology studies?
  • When to conduct a polymorph screening?

Careers

• Technician LC-MSMS
• Drug product formulation scientist
• Project Manager (CMC)
• Global Regulatory CMC Manager
•  Analytical Scientist of Nanomaterials
• Analytical Scientist NMR
• Technician, Analytical Sciences
• Validation Engineer
• Analist Immunochemie
• Analist Chromatografie
• Associate Scientist - Production
• Regulatory CMC Writer
• CMC Writer
• Scientist in Analytical Sciences of nanomaterials (PhD level)
• Analytical Scientist
• Drug Product Formulation Scientist
• Technician LC-MS/MS
• BSc/MSc in Analytical Chemistry

Testimonials

• Stijn
• Raja
• Maxime
• Ana